TW202400783A - 噬菌體 - Google Patents
噬菌體 Download PDFInfo
- Publication number
- TW202400783A TW202400783A TW112115666A TW112115666A TW202400783A TW 202400783 A TW202400783 A TW 202400783A TW 112115666 A TW112115666 A TW 112115666A TW 112115666 A TW112115666 A TW 112115666A TW 202400783 A TW202400783 A TW 202400783A
- Authority
- TW
- Taiwan
- Prior art keywords
- phage
- genome
- nucleic acid
- specified
- acid sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022075078 | 2022-04-28 | ||
| JP2022-075078 | 2022-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202400783A true TW202400783A (zh) | 2024-01-01 |
Family
ID=88518795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112115666A TW202400783A (zh) | 2022-04-28 | 2023-04-27 | 噬菌體 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4516898A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023210732A1 (cg-RX-API-DMAC7.html) |
| AR (1) | AR129166A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400783A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023210732A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122060690A (zh) * | 2026-04-01 | 2026-05-19 | 深圳市百泽诺科生物技术有限公司 | 一种分枝杆菌噬菌体及其应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4745231A1 (en) * | 2023-07-14 | 2026-05-20 | Arrowsmith Inc. | MODIFIED BACTERIOPHAGE |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010043924A1 (en) * | 1994-04-05 | 2001-11-22 | Exponential Biotherapies, Inc. | Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system |
| EP2579883A1 (en) * | 2010-06-08 | 2013-04-17 | Leah Robert | Bacteriophages for use against bacterial infections |
| EP3358015A1 (en) * | 2017-02-03 | 2018-08-08 | Eligo Bioscience | Optimized vector for delivery in microbial populations |
| US11066691B1 (en) * | 2018-09-14 | 2021-07-20 | National Technology & Engineering Solutions Of Sandia, Llc | Therapeutic phages and methods thereof |
| US12576118B2 (en) * | 2019-05-21 | 2026-03-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bacteriophages for the treatment of tuberculosis |
| CN114981408A (zh) * | 2019-11-06 | 2022-08-30 | 洛可斯生物科学公司 | Crispr cas系统和溶原性模块 |
| WO2021092362A1 (en) * | 2019-11-07 | 2021-05-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of specific phages for the treatment of nontuberculous mycobacteria (ntm) infections |
-
2023
- 2023-04-27 EP EP23796468.9A patent/EP4516898A4/en active Pending
- 2023-04-27 WO PCT/JP2023/016600 patent/WO2023210732A1/ja not_active Ceased
- 2023-04-27 JP JP2024518019A patent/JPWO2023210732A1/ja active Pending
- 2023-04-27 TW TW112115666A patent/TW202400783A/zh unknown
- 2023-04-27 AR ARP230101025A patent/AR129166A1/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122060690A (zh) * | 2026-04-01 | 2026-05-19 | 深圳市百泽诺科生物技术有限公司 | 一种分枝杆菌噬菌体及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AR129166A1 (es) | 2024-07-24 |
| EP4516898A4 (en) | 2026-05-06 |
| EP4516898A1 (en) | 2025-03-05 |
| WO2023210732A1 (ja) | 2023-11-02 |
| JPWO2023210732A1 (cg-RX-API-DMAC7.html) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8105579B2 (en) | Bacteriophage-containing therapeutic agents | |
| DE60113851T2 (de) | Bakteriophage mit breitem wirtsspektrum | |
| US20130295054A1 (en) | Modified Bacteria and their Uses thereof for the Treatment of Cancer or Tumor | |
| JP2020143119A (ja) | シュードモナス感染症のファージ治療 | |
| JP2023182703A (ja) | Staphylococcus感染症を処置するための治療的バクテリオファージ組成物 | |
| US20250170195A1 (en) | Bacteriophage compositions for treating pseudomonas infections | |
| EP4516898A1 (en) | Bacteriophage | |
| Adamczyk-Popławska et al. | The potential for bacteriophages and prophage elements in fighting and preventing the gonorrhea | |
| WO2025018295A1 (ja) | 改変バクテリオファージ | |
| Hoyle et al. | Phage therapy: bacteriophages as natural, self-replicating antimicrobials | |
| KR100949389B1 (ko) | 박테리오파지 kctc11120bp를 함유하는 세균증식 억제 또는 사멸용 제제 | |
| RU2717973C1 (ru) | Штамм бактериофага Pseudomonas aeruginosa N 322 (500316), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов | |
| RU2717451C1 (ru) | Штамм бактериофага Pseudomonas aeruginosa N 323 (500317), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов | |
| US12576118B2 (en) | Bacteriophages for the treatment of tuberculosis | |
| RU2831173C1 (ru) | Штамм бактериофага Pseudomonas phage Ka1 для лечения и/или профилактики инфекционных заболеваний, вызываемых Pseudomonas aeruginosa | |
| Ghazaei | A Comprehensive Review of Therapeutics Targeting Intracellular Bacteria: Current Insights and Emerging Approaches | |
| RU2808830C1 (ru) | Штамм бактериофага Pseudomonas phage Ka2 для профилактики и лечения инфекционных заболеваний, вызываемых Pseudomonas aeruginosa | |
| RU2717972C1 (ru) | Штамм бактериофага Pseudomonas aeruginosa N 324 (500318), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов | |
| US20250051733A1 (en) | Method of Generating Phage Clones with Expanded Activity | |
| RU2717435C1 (ru) | Штамм бактериофага Pseudomonas aeruginosa N 326 (500320), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов | |
| RU2717026C1 (ru) | Штамм бактериофага Pseudomonas aeruginosa N 325 (500319), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов | |
| EP4720263A1 (en) | Phage therapy utilizing a unique cocktail of pseudomonas aeruginosa phages | |
| De Soir | Exploring Phage-Antibiotic Synergies for the Treatment of Biofilm-related Infectious Diseases | |
| Yıldırım | Mediterr J Infect Microb Antimicrob 2022; 11: 43 Erişim: http://dx. doi. org/10.4274/mjima. galenos. 2022.2022. 43 | |
| Abdo Ahmad | Establishment of a Bacteriophages Platform: Alternative Therapeutic Option |